Immunotherapy for Hepatocellular Carcinoma: A 2021 Update
Hepatocellular carcinoma (HCC) is one of one of the most frequent liver cancers and the fourth leading cause of cancer-related mortality worldwide. Current treatment options such as surgery, neoadjuvant chemoradiotherapy, liver transplantation, and radiofrequency ablation will benefit only a very sm...
Main Authors: | Christo Kole, Nikolaos Charalampakis, Sergios Tsakatikas, Michail Vailas, Dimitrios Moris, Efthymios Gkotsis, Stylianos Kykalos, Michalis V. Karamouzis, Dimitrios Schizas |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/10/2859 |
Similar Items
-
Immunotherapy in Combination with Well-Established Treatment Strategies in Pancreatic Cancer: Current Insights
by: Kole C, et al.
Published: (2022-03-01) -
The Intriguing History of Cancer Immunotherapy
by: Paula Dobosz, et al.
Published: (2019-12-01) -
Current development in adenoviral vectors for cancer immunotherapy
by: Greyson Willis Grossman Biegert, et al.
Published: (2021-12-01) -
Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers
by: Lindsey Carlsen, et al.
Published: (2022-02-01) -
Editorial: Personalized immunotherapy for cancer
by: Anna Pasetto, et al.
Published: (2023-03-01)